<!DOCTYPE html >
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p34" style="overflow: hidden; position: relative; width: 935px; height: 1210px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_34{left:110px;top:1133px;letter-spacing:-0.1px;word-spacing:0.2px;}
#t2_34{left:459px;top:1133px;letter-spacing:0.3px;}
#t3_34{left:757px;top:1133px;word-spacing:-0.7px;}
#t4_34{left:220px;top:109px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t5_34{left:220px;top:131px;letter-spacing:-0.1px;}
#t6_34{left:220px;top:153px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t7_34{left:220px;top:175px;letter-spacing:-0.1px;}
#t8_34{left:220px;top:197px;letter-spacing:-0.1px;}
#t9_34{left:220px;top:220px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#ta_34{left:275px;top:242px;}
#tb_34{left:220px;top:264px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tc_34{left:275px;top:286px;}
#td_34{left:220px;top:308px;letter-spacing:-0.1px;}
#te_34{left:275px;top:330px;}
#tf_34{left:220px;top:352px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tg_34{left:220px;top:375px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#th_34{left:220px;top:397px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#ti_34{left:220px;top:419px;letter-spacing:-0.1px;}
#tj_34{left:220px;top:441px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tk_34{left:220px;top:463px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tl_34{left:220px;top:485px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tm_34{left:220px;top:507px;letter-spacing:-0.1px;}
#tn_34{left:220px;top:529px;letter-spacing:-0.1px;word-spacing:0.1px;}
#to_34{left:220px;top:552px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tp_34{left:220px;top:574px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tq_34{left:220px;top:596px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tr_34{left:220px;top:618px;letter-spacing:-0.1px;word-spacing:0.1px;}
#ts_34{left:220px;top:640px;letter-spacing:-0.1px;}
#tt_34{left:220px;top:662px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tu_34{left:220px;top:684px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tv_34{left:220px;top:706px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tw_34{left:220px;top:729px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tx_34{left:220px;top:751px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#ty_34{left:220px;top:773px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#tz_34{left:220px;top:795px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#t10_34{left:220px;top:817px;letter-spacing:-0.1px;word-spacing:-0.3px;}
#t11_34{left:220px;top:839px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t12_34{left:220px;top:862px;letter-spacing:-0.1px;}
#t13_34{left:220px;top:884px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t14_34{left:275px;top:906px;}
#t15_34{left:220px;top:928px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t16_34{left:220px;top:950px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#t17_34{left:275px;top:972px;letter-spacing:-0.1px;}
#t18_34{left:220px;top:994px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t19_34{left:220px;top:1016px;letter-spacing:-0.1px;}
#t1a_34{left:220px;top:1039px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t1b_34{left:220px;top:1061px;letter-spacing:-0.1px;}

.s1_34{
	FONT-SIZE: 67.5px;
	FONT-FAMILY: Calibri_f8x;
	color: rgb(0,0,0);
}

</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts34" type="text/css" >

@font-face {
	font-family: Calibri_f8x;
	src: url("fonts/Calibri_f8x.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg34Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg34" style="-webkit-user-select: none;"><object width="935" height="1210" data="34/34.svg" type="image/svg+xml" id="pdf34" style="width:935px; height:1210px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div id="t1_34" class="t s1_34">Medicare FFS Claims (Version K) Codebook</div>
<div id="t2_34" class="t s1_34">31</div>
<div id="t3_34" class="t s1_34">May 2017</div>
<div id="t4_34" class="t s1_34">0828 = Gemcitabine HCL 200 mg (eligible for pass-through payments) </div>
<div id="t5_34" class="t s1_34">0830 = Irinotecan 20 mg (eligible for pass-through payments) </div>
<div id="t6_34" class="t s1_34">0831 = Ifosfamide injection 1 gm (eligible for pass-through payments) </div>
<div id="t7_34" class="t s1_34">0832 = Idarubicin HCL injection 5 mg (eligible for pass-through payments) </div>
<div id="t8_34" class="t s1_34">0833 = Interferon Alfacon-1, 1 mcg (eligible for pass-through payments) </div>
<div id="t9_34" class="t s1_34">0834 = Interferon, Alfa-2A, Recombinant 3 million units (eligible for pass-through </div>
<div id="ta_34" class="t s1_34">payments) </div>
<div id="tb_34" class="t s1_34">0836 = Interferon, Alfa-2B, Recombinant, 1 million units (eligible for pass-through </div>
<div id="tc_34" class="t s1_34">payments) </div>
<div id="td_34" class="t s1_34">0838 = Interferon, Gamma 1-B injection, 3 million units (eligible for pass-through </div>
<div id="te_34" class="t s1_34">payments) </div>
<div id="tf_34" class="t s1_34">0839 = Mechlorethamine HCL injection 10 mg (eligible for pass-through payments) </div>
<div id="tg_34" class="t s1_34">0840 = Melphalan HCL 50 mg (eligible for pass-through payments) </div>
<div id="th_34" class="t s1_34">0841 = Methotrexate sodium injection 5 mg (eligible for pass-through payments) </div>
<div id="ti_34" class="t s1_34">0842 = Fludarabine Phosphate injection 50 mg (eligible for pass-through payments) </div>
<div id="tj_34" class="t s1_34">0843 = Pegaspargase, single dose vial (eligible for pass-through payments) </div>
<div id="tk_34" class="t s1_34">0844 = Pentostatin injection, 10 mg (eligible for pass-through payments) </div>
<div id="tl_34" class="t s1_34">0847 = Doxorubicin HCL 10 mg (eligible for pass-through payments) </div>
<div id="tm_34" class="t s1_34">0849 = Rituximab, 100 mg (eligible for pass-through payments) </div>
<div id="tn_34" class="t s1_34">0850 = Streptozocin injection, 1 gm (eligible for pass-through payments) </div>
<div id="to_34" class="t s1_34">0851 = Thiotepa injection, 15 mg (eligible for pass-through payments) </div>
<div id="tp_34" class="t s1_34">0852 = Topotecan 4 mg (eligible for pass-through payments) </div>
<div id="tq_34" class="t s1_34">0853 = Vinblastine Sulfate injection, 1 mg (eligible for pass-through payments) </div>
<div id="tr_34" class="t s1_34">0854 = Vincristine Sulfate 1 mg (eligible for pass-through payments) </div>
<div id="ts_34" class="t s1_34">0855 = Vinorelbine Tartrate per 10 mg (eligible for pass-through payments) </div>
<div id="tt_34" class="t s1_34">0856 = Porfimer Sodium 75 mg (eligible for pass-through payments) </div>
<div id="tu_34" class="t s1_34">0857 = Bleomycin Sulfate injection 15 units (eligible for pass-through payments) </div>
<div id="tv_34" class="t s1_34">0858 = Cladribine, 1mg (eligible for pass-through payments) </div>
<div id="tw_34" class="t s1_34">0859 = Fluorouracil injection 500 mg </div>
<div id="tx_34" class="t s1_34">0860 = Plicamycin (mithramycin) injection, 2.5 mg </div>
<div id="ty_34" class="t s1_34">0861 = Leuprolide Acetate 1 mg (eligible for pass-through payments) </div>
<div id="tz_34" class="t s1_34">0862 = Mitomycin, 5mg (eligible for pass-through payments) </div>
<div id="t10_34" class="t s1_34">0863 = Paclitaxel, 30mg (eligible for pass-through payments) </div>
<div id="t11_34" class="t s1_34">0864 = Mitoxantrone HCl, per 5mg (eligible for pass-through payments) </div>
<div id="t12_34" class="t s1_34">0865 = Interferon alfa-N3, 250,000 IU (eligible for pass-through payments) </div>
<div id="t13_34" class="t s1_34">0884 = Rho (D) Immune Globulin, Human one dose pack (eligible for pass-through </div>
<div id="t14_34" class="t s1_34">payments) </div>
<div id="t15_34" class="t s1_34">0886 = Azathioprine, 50 mg oral (Not subject to national coinsurance) </div>
<div id="t16_34" class="t s1_34">0887 = Azathioprine, Parenteral 100 mg, 20 ml each injection (Not subject to national </div>
<div id="t17_34" class="t s1_34">coinsurance) </div>
<div id="t18_34" class="t s1_34">0888 = Cyclosporine, Oral 100 mg (Not subject to national coinsurance) </div>
<div id="t19_34" class="t s1_34">0889 = Cyclosporine, Parenteral (Not subject to national coinsurance) </div>
<div id="t1a_34" class="t s1_34">0890 = Lymphocyte Immune Globulin 250 mg (Not subject to national coinsurance) </div>
<div id="t1b_34" class="t s1_34">0891 = Tacrolimus per 1 mg oral (Not subject to national coinsurance) </div>

<!-- End text definitions -->


</div>
</body>
</html>
